参考文献/References:
[1] Wang F,Yang C,Long J,et al. Executive summary for the 2015 annual data report of?the China kidney disease network (ck-net)[J]. Kidney Int,2019,95(3):501-505.
[2] Sarnak MJ,Amann K,Bangalore S,et al. Chronic kidney disease and coronary?artery disease:Jacc state-of-the-art review[J]. J Am Coll Cardiol,2019,74(14):1823-1838.
[3] Ferro CJ,Mark PB,Kanbay M,et al. Lipid management in patients with chronic kidney disease[J]. Nat Rev Nephrol,2018,14(12):727-749.
[4] Florens N,Calzada C,Lyasko E,et al. Modified lipids and lipoproteins in chronic kidney disease:a new class of uremic toxins [J]. Toxins (Basel),2016,8(12):376.
[5] Lamprea-Montealegre JA,Staplin N,Herrington WG,et al. Apolipoprotein b,triglyceride-rich lipoproteins,and risk of cardiovascular events in persons with ckd[J]. Clin J Am Soc Nephrol,2020,15(1):47-60.
[6] Teramoto R,Tada H,Kawashiri MA,et al. Molecular and functional characterization of familial chylomicronemia syndrome[J]. Atherosclerosis,2018,269:272-278.
[7] Reiner ?. Hypertriglyceridaemia and risk of coronary artery disease[J]. Nat Rev Cardiol,2017,14(7):401-411.
[8] Sandesara PB,Virani SS,Fazio S,et al. The forgotten lipids:triglycerides,remnant cholesterol,and atherosclerotic cardiovascular disease risk[J]. Endocr Rev,2019,40(2):537-557.
[9] Bermúdez-López M,Arroyo D,Betriu ?,et al. New perspectives on ckd-induced dyslipidemia[J]. Expert Opin Ther Targets,2017,21(10):967-976.
[10] Mikolasevic I,?utelija M,Mavrinac V,et al. Dyslipidemia in patients with chronic kidney disease:Etiology and management[J]. Int J Nephrol Renovasc Dis,2017,10:35-45.
[11] Rapa SF,di Iorio BR,Campiglia P,et al. Inflammation and oxidative stress in chronic kidney disease-potential therapeutic role of minerals,vitamins and plant-derived metabolites[J]. Int J Mol Sci,2019,21(1):263.
[12] Liakopoulos V,Roumeliotis S,Gorny X,et al. Oxidative stress in hemodialysis patients:A review of the literature[J]. Oxid Med Cell Longev,2017,2017:3081856.
[13] Düsing P,Zietzer A,Goody PR,et al. Vascular pathologies in chronic kidney disease:Pathophysiological mechanisms and novel therapeutic approaches[J]. J Mol Med (Berl),2021,99(3):335-348.
[14] Krata N,Zago?d?on R,Foroncewicz B,et al. Oxidative stress in kidney diseases:the cause or the consequence?[J]. Arch Immunol Ther Exp (Warsz),2018,66(3):211-220.
[15] Daenen K,Andries A,Mekahli D,et al. Oxidative stress in chronic kidney disease[J]. Pediatr Nephrol,2019,34(6):975-991.
[16] Castillo-Rodríguez E,Pizarro-Sánchez S,Sanz AB,et al. Inflammatory cytokines as uremic toxins:"Ni son todos los que estan,ni estan todos los que son"[J]. Toxins (Basel),2017,9(4):114.
[17] Valdivielso JM,Rodríguez-Puyol D,Pascual J,et al. Atherosclerosis in chronic kidney disease:More,less,or just different?[J]. Arterioscler Thromb Vasc Biol,2019,39(10):1938-1966.
[18] Rogacev KS,Seiler S,Zawada AM,et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease [J]. Eur Heart J,2011,32(1):84-92.
[19] Roy-Chowdhury E,Brauns N,Helmke A,et al. Human CD16+ monocytes promote a pro-atherosclerotic endothelial cell phenotype via CX3CR1-CX3CL1 interaction [J]. Cardiovasc Res,2021,117(6):1510-1522.
[20] Chiu YL,Shu KH,Yang FJ,et al. A comprehensive characterization of aggravated aging-related changes in T lymphocytes and monocytes in end-stage renal disease:the iESRD study[J]. Immun Ageing,2018,15:27.
[21] Wang XR,Zhang JJ,Xu XX,et al. Prevalence of coronary artery calcification and its association with mortality,cardiovascular events in patients with chronic kidney disease:a systematic review and meta-analysis [J]. Ren Fail,2019,41(1):244-256.
[22] Goodman WG,Goldin J,Kuizon BD,et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis[J]. N Engl J Med,2000,342(20):1478-1483.
[23] Vervloet M,Cozzolino M. Vascular calcification in chronic kidney disease:different bricks in the wall?[J]. Kidney Int,2017,91(4):808-817.
[24] Hsu BG,Tsai JP. Vascular calcification of chronic kidney disease:a brief review [J]. Tzu Chi Med J,2021,33(1):34-41.
[25] Wei X,Wu W,Li L,et al. Bone morphogenetic proteins 2/4 are upregulated during the early development of vascular calcification in chronic kidney disease[J]. Biomed Res Int,2018,2018:8371604.
[26] Stubbs J,Liu S,Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease[J]. Semin Dial,2007,20(4):302-308.
[27] Barali? M,Brkovi? V,Stojanov V,et al. Dual roles of the mineral metabolism disorders biomarkers in prevalent hemodilysis patients:in renal bone disease and in vascular calcification[J]. J Med Biochem,2019,38(2):134-144.
[28] Moe SM,Chertow GM,Parfrey PS,et al. Cinacalcet,fibroblast growth factor-23,and cardiovascular disease in hemodialysis:the evaluation of cinacalcet hcl therapy to lower cardiovascular events (evolve) trial[J]. Circulation,2015,132(1):27-39.
[29] Fitzpatrick J,Kim ED,Sozio SM,et al. Calcification biomarkers,subclinical vascular disease,and mortality among multiethnic dialysis patients[J]. Kidney Int Rep,2020,5(10):1729-1737.
[30] Benz K,Hilgers KF,Daniel C,et al. Vascular calcification in chronic kidney disease:the role of inflammation[J]. Int J Nephrol,2018,2018:4310379.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(8):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(8):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(8):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(8):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(8):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(8):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(8):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(8):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(8):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(8):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]